

Special Issue

Novel Challenges and Advances in Thoracic Surgery

Message from the Guest Editor

Thanks to the significant advancement of technology (both in surgery and oncology), the advent of artificial intelligence, and the innovation of new drugs in the treatment of lung cancer, in the last 15 days we witnessed an important improvement in the medical care of patients affected by lung cancer, with extraordinary oncological and medical results. We aim to publish articles describing novel challenges and advances in thoracic surgery, from minimally invasive and robotic surgery for early or locally advanced lung cancer to more complex cases, including post-neoadjuvant (immuno or biological therapy) surgery. In this Special Issue, we aim to explore electromagnetic navigation bronchoscopy, 3D techniques, and medically innovative treatments. Investigating all new therapeutic and surgical possibilities in the field of thoracic oncology. Evaluating the potential advantages of minimally invasive surgery, target therapy, and immunotherapy in the treatment of early and advanced lung cancer. We encourage the submission of manuscripts that describe all novel challenges and advances in the treatment of lung cancer, both surgical and medical.

Guest Editor

Dr. Antonio Mazzella

Division of Thoracic Oncology, European Institute of Oncology (IEO),
Milano, Italy

Deadline for manuscript submissions

closed (10 February 2025)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/207704

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).